Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript
03:56pm, Tuesday, 04'th Nov 2025
HUTCHMED (China) Limited ( HCM ) HUTCHMED (China) Limited Deutsche Bank ADR Virtual Investor Conference 2025 November 4, 2025 8:00 AM EST Company Participants David Ng - Head of Investor Relations & C
HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
07:00pm, Sunday, 02'nd Nov 2025
— HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —
HUTCHMED (China) Limited ( HCM ) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update October 31, 2025 8:00 AM EDT Company Participants David Ng - Head of
Terrestrial Energy Inc. Completes Business Combination with HCM II Acquisition Corp.
05:19pm, Tuesday, 28'th Oct 2025
Terrestrial Energy to begin trading on the Nasdaq Stock Market under ticker symbol “IMSR” on October 29, 2025 The transaction closed with gross proceeds exceeding $292 million before expenses, ref
HCM II Acquisition Corp. Shareholders Approve Business Combination with Terrestrial Energy
05:37pm, Monday, 20'th Oct 2025
CHARLOTTE, N.C. and STAMFORD, Conn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- HCM II Acquisition Corp. (Nasdaq: HOND) (“HCM II”), a special-purpose acquisition company, is pleased to announce that in an
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
04:30am, Tuesday, 14'th Oct 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Pro
HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
12:00am, Monday, 13'th Oct 2025
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal cell carcinoma patients after progression on first-line therapies The fruquintinib and sintilima
Aims to standardize HR processes, enhance employee productivity and experience BENGALURU, India , Oct. 3, 2025 /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in next-g
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
08:00pm, Wednesday, 01'st Oct 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data fro
CHARLOTTE, N.C. & STAMFORD, Conn.--(BUSINESS WIRE)--HCM II Acquisition Corp. (Nasdaq: HOND) (“HCM II”), a special-purpose acquisition company and Terrestrial Energy Inc. (“Terrestrial Energy”
Stamford, CT, Sept. 19, 2025 (GLOBE NEWSWIRE) -- HCM III Acquisition Corp. (NASDAQ: HCMAU) (the “Company”) announced today that, commencing September 22, 2025, holders of the units sold in the Com
Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025
08:00pm, Thursday, 11'th Sep 2025
— HUTCHMED will host in-person presentation and online webinar on Friday, October 31 — — HUTCHMED will host in-person presentation and online webinar on Friday, October 31 —
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
08:00pm, Thursday, 04'th Sep 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data fr
Largest Noninterventional Natural History Study of People Under 18 with MYBPC3-associated HCM with More than 200 Participants
HUTCHMED Announces Appointment of Acting Chief Executive Officer
08:20pm, Sunday, 24'th Aug 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that Dr Weiguo Su, an Executiv
